Urologic Neoplasms  >>  Lipotecan (TLC388)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipotecan (TLC388) / Taiwan Liposome Company
NCT01831973: A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

Completed
2
18
RoW
Lipotecan, TLC388
Taiwan Liposome Company
Advanced/Metastasis Renal Cell Carcinoma
03/15
02/17

Download Options